Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Tigecycline.

George A Pankey¹

¹Infectious Diseases Research, Ochsner Clinic Foundation LT 7S, 1514 Jefferson Highway, New Orleans, LA 70121-2483, USA. gpankey@ochsner.org

The Journal of Antimicrobial Chemotherapy

|July 26, 2005

Summary

The urgent need for new antibiotics is met by tigecycline, a novel glycylcycline agent effective against many multidrug-resistant bacteria. Clinical trials are underway to assess its promise for treating severe infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Antimicrobial and resource utilization with T2 magnetic resonance for rapid diagnosis of bloodstream infections: systematic review with meta-analysis of controlled studies.

Expert review of medical devices·2021

Same author

In vitro interaction of fluconazole and trimethoprim-sulfamethoxazole against <i>Candida auris</i> using ETEST and checkerboard methods.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2020

Same author

Evaluation of the in vitro interaction of fosfomycin and meropenem against metallo-β-lactamase-producing <i>Pseudomonas aeruginosa</i> using Etest and time-kill assay.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2020

Same author

Performance of the T2Bacteria Panel for Diagnosing Bloodstream Infections: A Diagnostic Accuracy Study.

Annals of internal medicine·2019

Same author

Synergistic effect between nisin and polymyxin B against pandrug-resistant and extensively drug-resistant Acinetobacter baumannii.

International journal of antimicrobial agents·2019

Same author

In vitro synergy with fluconazole plus doxycycline or tigecycline against clinical Candida glabrata isolates.

Medical mycology·2018

Area of Science:

Microbiology
Infectious Diseases
Pharmacology

Background:

Increasing prevalence of multidrug-resistant bacteria necessitates novel antimicrobial agents.
Existing resistance mechanisms limit the efficacy of current antibiotics.
Tigecycline, a glycylcycline, is designed to overcome tetracycline resistance.

Purpose of the Study:

To evaluate the in vitro activity of tigecycline against key multidrug-resistant pathogens.
To assess the potential of tigecycline as a therapeutic option for serious infections.

Main Methods:

In vitro susceptibility testing of tigecycline against various resistant bacterial strains.
Evaluation of tigecycline's efficacy against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
Assessment of activity against multidrug-resistant Gram-negative bacteria.

Main Results:

Tigecycline demonstrated activity against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
Broad-spectrum activity was observed against many multidrug-resistant Gram-negative bacteria.
Emerging resistance noted in Pseudomonas aeruginosa and reduced susceptibility in Proteus species.

Conclusions:

Tigecycline shows promise as a novel antibiotic with an expanded spectrum of activity.
It effectively combats many multidrug-resistant organisms, addressing a critical clinical need.
Further clinical evaluation in Phase III trials is ongoing for serious infections.

Related Experiment Videos